Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of aflibercept-treated patients from VGFTe-ROP-1920
2024-513231-24-00Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in retinopathy of prematurity (ROP), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Binocular best-corrected visual acuity, Proportion of patients with adverse events and 1 more. Started Mar 2022; status: completed.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2024-513231-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513231-24-00.